Article Details

TARIS CEO Purnanand Sarma Says $25 Million Series B Funding Will Focus on Bladder Cancer ...

Retrieved on: 2018-01-25 10:48:45

Tags for this article:

Click the tags to see associated articles and topics

TARIS CEO Purnanand Sarma Says $25 Million Series B Funding Will Focus on Bladder Cancer .... View article details on hiswai:

Excerpt

<div>LEXINGTON, MA–ARIS Biomedical LLC, which is developing targeted new therapies for patients suffering from difficult-to-treat bladder diseases, has raised $25 million in a Series B financing. The new funding will be used to “to further advance both our programs- bladder cancer and overactive bladder, ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up